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Abstract
Background: In 2002 a Meningococcal serogroup C (MenC) conjugate vaccine, with tetanus toxoid as carrier protein, was
introduced in the Netherlands as a single-dose at 14 months of age. A catch-up campaign was performed targeting all
individuals aged 14 months to 18 years. We determined the MenC-specific immunity before and after introduction of the
MenC conjugate (MenCC) vaccine.
Methods and Findings: Two cross-sectional population-based serum banks, collected in 1995/1996 (n=8539) and in 2006/
2007 (n=6386), were used for this study. The main outcome measurements were the levels of MenC polysaccharide(PS)-
specific IgG and serum bactericidal antibodies (SBA) after routine immunization, 4–5 years after catch-up immunization or
by natural immunity. There was an increasing persistence of PS-specific IgG and SBA with age in the catch-up immunized
cohorts 4–5 years after their MenCC immunization (MenC PS-specific IgG, 0.25 mg/ml (95%CI: 0.19–0.31 mg/ml) at age 6
years, gradually increasing to 2.34 mg/ml,(95%CI: 1.70–3.32 mg/ml) at age 21–22 years). A comparable pattern was found for
antibodies against the carrier protein in children immunized above 9 years of age. In case of vaccination before the age of 5
years, PS-specific IgG was rapidly lost. For all age-cohorts together, SBA seroprevalence ($8) increased from 19.7% to 43.0%
in the pre- and post-MenC introduction eras, respectively. In non-immunized adults the SBA seroprevalence was not
significantly different between the pre- and post-MenC introduction periods, whereas PS-specific IgG was significantly lower
in the post-MenC vaccination (GMT, age $25 years, 0.10 mg/ml) era compared to the pre-vaccination (GMT, age $25 years,
0.43 mg/ml) era.
Conclusion: MenCC vaccination administered above 5 years of age induced high IgG levels compared to natural exposure,
increasing with age. In children below 14 months of age and non-immunized cohorts lower IgG levels were observed
compared to the pre-vaccination era, whereas functional levels remained similar in adults. Whether the lower IgG poses
individuals at increased risk for MenC disease should be carefully monitored. Large-scale introduction of a MenCC vaccine
has led to improved protection in adolescents, but in infants a single-dose schedule may not provide sufficient protection
on the long-term and therefore a booster-dose early in adolescence should be considered.
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Introduction
In September 2002, a single Meningococcal serogroup C
conjugate (MenCC, Neisvac-C, Baxter, IL, USA) vaccination at
the age of 14 months was introduced for all newborns in the
Dutch national immunization programme (NIP). The reason to
include MenCC vaccination in the NIP was the rapidly
progressive increase in the incidence of MenC disease in
2000–2001 [1]. The decision for a single dose schedule at 14
months of age was based on epidemiological, programmatical
and economical reasons [2]. Next to vaccination of all 14-
month-old children, a catch-up campaign was conducted
between June and November 2002 for all children and
adolescents between 1 and 18 years of age, who were invited
to receive a single MenCC dose (overall vaccine coverage 94%)
[3]. Soon afterwards, MenC disease disappeared in vaccinated
p e r s o n s ,a n das h a r pd e c l i n ew a so b s e r v e di nn o n - i m m u n i z e d
cohorts [1].
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month of age and a catch-up campaign, different MenCC vaccine
schedules were introduced within Europe. The United Kingdom
and Spain implemented a 3-dose primary series at 2, 3 and 4
months and 2, 4 and 6 months of age, respectively. However,
already within the first year after the last scheduled dose in infancy
low effectiveness was observed [4,5]. This was explained by rapidly
waning antibody titers after vaccinations early in life without a
later booster. Afterwards, the UK changed the vaccination
schedule to 2 priming doses at 3 and 4 months of age followed
by a booster dose at 12 months [6]. Rapid waning of circulating
antibodies was also observed in the UK after a single dose in the
second year of life [7,8]. In contrast, when MenCC vaccine was
administered at older ages, between 6 and 18 years, a single
vaccination, resulted in persistently high antibody levels and
(bactericidal) antibody levels up to at least five years after
vaccination [9,10].
In the Netherlands, no vaccine failures have been reported and
only sporadic cases of MenC disease in non-immunized age-cohorts
have occurred, indicating low transmission due to ongoing herd-
effects after introduction of vaccination. However, monitoring the
persistence of vaccine-induced protection in various age categories
after a single immunization remains relevant since widespread
introduction of the conjugate vaccine has led to reduced circulation,
leading to a lack in natural boosting, eventually resulting in pos-
sible waning immunity in both vaccinated and non-vaccinated
age-cohorts.
A widely accepted correlate of protection for MenC disease is
the outcome of a serum bactericidal antibody (SBA) assay [11,12].
MenC polysaccharide-specific immunoglobulin type G (IgG)
responses may provide insight in naturally-acquired or vaccine-
induced immunity [10,13,14]. Here we describe the seropreva-
lence of MenC polysaccharide-specific antibody concentrations
and functional SBA titres in two cross-sectional population-based
serum sets, collected several years before (1995/6) and after
introduction (2006/7) of the MenCC vaccine in 2002. Further-
more, the MenCC vaccine administered in the Dutch NIP
contains tetanus toxoı ¨d as the carrier protein. For this reason we
also examined antibody levels directed towards tetanus in age-
cohorts who received a MenCC immunization during the catch-
up campaign in 2002.
Methods
The study proposal was approved by the Medical Ethics Testing
Committee of the foundation of therapeutic evaluation of
medicines (METC-STEG) in Almere (clinical trial number:
ISRCTN 20164309) and all participants provided signed informed
consent.
Study population
Two independent cross-sectional population-based serosurveil-
lance studies were carried out in the Netherlands between October
1995- December 1996 (n=8539) and February 2006- June 2007
(n=6386) (ISRCTN 20164309). Both studies had the same design
which has been described previously [15,16]. Briefly, a sample of
eight municipalities was drawn proportional to the number of
inhabitants in five geographical regions of approximately equal
population size in the Netherlands. Within each municipality an
age-stratified sample (0, 1–4, 5–9, . . ., 75–79 years) of 380–500
persons (males and females) was drawn. The first two age strata
were over-sampled due to an expected lower response rate in these
groups. In total 17,341 persons were invited in the nationwide
sample. An extra sample of non-Western migrants was taken from
12 of the 40 municipalities in the nationwide sample. In total 2,574
migrants were invited. Eligible individuals were requested to
donate a blood sample, to complete a questionnaire (questions
regarding demographic characteristics, vaccination history, health
perception and diseases, and activities possibly related to infectious
diseases (e.g. travelling, profession, gardening)), and to provide
immunization records. The immunization history of the partici-
pants was checked by copies of immunization certificates and
information obtained from regional immunization administration
office archives. All participants gave signed informed consent.
Collected serum samples were stored at 280uC until analysis.
From the pre-immunization era, 2303 sera were randomly
selected and tested for detection of MenC-specific IgG, and from
these samples 735 were randomly selected (equally distributed over
age and blinded to the IgG result) and tested for MenC-specific
SBA. Sufficient amount of serum was available for 6376 samples
from the post-immunization era and these were tested for
meningococcal serogroup A2,C 2,Y 2 and W-135-specific IgG
and from these samples 1220 were randomly selected (again
equally distributed over age and blinded to IgG result) and tested
for MenC-specific SBA. Laboratory staff was blinded to sample
characteristics (e.g. age, gender, et cetera) during analysis and all
analyses were performed in 2007/8.
Laboratory methods
Meningococcal polysaccharide-specific IgG was determined by
a fluorescent-bead-based multiplex immunoassay (MIA) as previ-
ously described [17]. Tetanus-specific antibodies were determined
with a MIA as described previously by Van Gageldonk et al [18].
Samples were analyzed using a Bio-Plex system in combination
with the Bio-Plex Manager software version 4.1.1 (Bio-Rad
Laboratories, Hercules, CA). For each analyte, median fluorescent
intensity was converted to mg/ml (meningococcal serogroups) or
international units (IU)/ml (tetanus) by interpolation from a 5-
parameter logistic standard curve. A concentration of 2 mg/ml was
used as cut-off in the MIA, which is internationally accepted as
standard [13,14]. The lower limit of quantitation for all four
meningococcal serogroups was assigned at 0.01 mg/ml and for
tetanus at 0.005 IU/ml for statistical purposes.
The level of MenC-specific functional antibodies was deter-
mined by a serum bactericidal antibody assay (SBA) using baby
rabbit complement [19], and the O-acetylated serogroup C strain
C11 (phenotype C:16:P1.7–1,1). SBA titres were expressed as the
reciprocal of the final serum dilution yielding $50% killing at
60 min. A titer of 8 was used as cut-off in the SBA, which is
internationally accepted as standard [10,11,12]. SBA titres ,4
were assigned a value of 2 for statistical purposes. The SBA
measurements were performed as a post-hoc analysis to the
original protocol.
Statistical analysis
Data analyses were performed in SAS 9.1.3 (SAS Institute Inc.
Cary, NC, USA). Seroprevalences and geometric mean concen-
trations (GMC) or geometric mean titers (GMT) of meningococcal
serogroup-specific IgG and serum bactericidal activity, respective-
ly, were calculated for the pre- and postvaccination survey in
different age-cohorts and weighted. In addition, GMCs of tetanus
specific antibodies were calculated and weighted. Weights were
determined proportional to the reference population (Dutch
population, 1
st of January 1997 for the pre-MenC introduction
study and 1
st of January 2007 for the post-MenC introduction
study), taking into account sex and age. For the post-MenC
vaccination study the degree of urbanization and ethnicity
were also taken into account because of the additional sample of
MenC-Specific Seroprevalence
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nationwide sample. The stratified age-bands from the original
protocol were adjusted post-hoc, to enable a better separation of
the age-cohorts with respect to their MenC immunization status.
Age-specific differences in MenC IgG levels between the pre- and
postvaccination surveys in each age-cohort were determined by a
Wilcoxon two-sided Z-test. Likewise, differences in MenC-specific
SBA seroprevalence (antibody titers $8) were determined by a
chi-square distribution (LR chi-square probability) or two-sided
Fisher’s exact test, as appropriate. No multiplicity was taken into
account since only pre- and post-MenC introduction data within
each age-cohort were compared and the age-cohorts were not
mutually compared. The Spearman rank correlation was used to
estimate the correlation between age-specific IgG levels and SBA
seroprevalence. P-values of ,0.05 were considered statistically
significant.
Results
Study characteristics
Samples from the pre-MenC introduction study were collected
between October 1995 and December 1996, median 6.6 (SD, 0.3)
years before introduction of MenCC vaccination in the Nether-
lands in 2002. Samples from the post-MenC introduction era were
collected between February 2006 and June 2007, a median of 4.3
years (SD, 0.4) after widespread implementation of MenCC
vaccination in 2002. MenC immunization dates were available for
82% (n=1273) of the individuals in cohorts eligible for MenCC
vaccination: either by routine immunization at 14 months of age
or during the catch-up campaign in 2002.
MenC-specific antibody levels in the pre-MenC
introduction era
Before introduction of the MenCC vaccine, in general, low
MenC-specific IgG levels were observed, with an overall GMC of
0.37 mg/ml. The lowest levels were observed under 5 years of age
(GMC 0.18 mg/ml, ages 0–5 years). After the age of 11–12 years, a
small increase in IgG was observed (GMC 0.22 mg/ml, at 11–12
years of age) until the age-cohort of 26–30 years (GMC 0.63 mg/
ml), after which antibody levels stabilized at a lower level (Fig. 1A,
Table 1). The prevalence of SBA titers $8 in the pre-MenC
introduction era followed a similar pattern. A low prevalence of
functional SBA titers under 6 years of age, hereafter, the
prevalence of putative protective SBA levels increased from 11%
at the ages 9–10 years of age to 26% at the ages 22–25 years. In
cohorts over 22 years of age on average 23% revealed SBA titers
$8 (Fig. 1B, Table 2).
MenC specific antibody levels in the post-MenC
introduction era
After implementation of routine MenCC vaccination at 14
months of age in 2002, MenC-specific IgG levels under 14 months
of age were significantly lower in 2006/2007 compared to the
levels in 1996/1997 (P,0.0001) (Fig. 1A, Table 1). None of the
tested sera of infants under 7 months and only 3% of those
between 8 and 14 months of age revealed putative protective SBA
levels $8 in the post-MenC introduction era. From the pre-MenC
introduction era only a few samples of infants under 14 months
(n=16) were available for SBA testing and none of these samples
revealed a SBA titer $8.
After introduction of vaccination, a clear rise in MenC-specific
IgG and functional antibodies was observed in the age-cohort 15–
23 months (Fig. 1A and B). In accordance, the prevalence of
SBA titers $8 in infants between 15 and 23 months of age was
92.6% (MenC-specific IgG GMC, 2.43 mg/ml). However, after
this peak in antibody levels, a steep decline in IgG antibodies was
found (Fig. 1A, Table 1), and IgG antibody concentrations had
decreased to pre-MenC introduction era levels in children between
23 and 72 months of age. SBA levels also had declined in the years
following immunization at 14 months but remained well above the
SBA levels observed in the pre-introduction era (P,0.0001)
(Fig. 1B, Table 2).
Individuals, who had been vaccinated with a single injection
between 14 months and 18 years of age during the catch-up
campaign in 2002, were 5 to 22 years of age during the post-
MenC introduction study in 2006/7. Children aged 6–9 years in
the post-MenC introduction survey revealed the lowest MenC-
specific IgG levels (GMC 0.24 mg/ml), which were comparable to
the pre-MenC introduction era levels (GMC 0.25 mg/ml) in the
same age-cohorts (Fig. 1A, Table 1). Nonetheless, the
prevalence of functional SBA titers was higher in the age-cohort
6 to 9 years compared with the pre-introduction era (P,0.05)
(Fig. 1B, Table 2). Remarkably, MenC-specific IgG and SBA
titers had increased gradually with age for children vaccinated
between 5 and 18 years of age and were significantly higher than
in the pre-MenC introduction era (P,0.0001) (Fig. 1A and B).
IgG levels had increased from 0.36 mg/ml in the cohort 9–10 years
of age to a level of 2.34 mg/ml in the ages 21–22 years and the
SBA prevalence $8 had increased from 45.2% to 95.5% in the
age-cohorts 9–10 and 19–21 years, respectively. The prevalence of
SBA titers $8 in the post-MenC introduction era in cohorts over
25 years of age was again comparable to the pre-MenC
introduction era: 21% and 23%, respectively. In non-immunized
cohorts aged 25 years and over, MenC-specific IgG levels were
significantly lower in the post-MenC introduction era (GMT age
$25 years, 0.10 mg/ml) compared with pre- introduction (GMT
age $25 years, 0.43 mg/ml) levels.
Overall, in all age categories together, a higher GMC of MenC-
specific IgG was observed before introduction of the MenCC
vaccine in 2002 (GMC 0.37 mg/ml), compared with the post-
MenC introduction era (GMC 0.17 mg/ml). In contrast, the
overall seroprevalence of SBA titers $8 was higher after wide-
spread introduction of MenC vaccination than before, 43.0% vs
19,7% respectively. The age-specific IgG levels and SBA titers
correlated well in the post-MenC introduction era (R=0.72).
Before MenC introduction little correlation was observed between
IgG and SBA levels (R=0.32).
With respect to non-MenC IgG antibody levels in the post-
MenC introduction era, meningococcal serogroups W-135 and –Y
-specific IgG levels were low in all age categories (Fig. 2).
Meningococcal serogroup A-specific IgG however increased with
age and was significantly higher than MenC-specific IgG above 25
years of age (P,0.0001) (Fig. 2).
Tetanus-specific antibodies in the pre- and post-MenC
introduction eras
In children below 9 years (who did not yet receive DT-IPV
booster at 9 years of age) tetanus-specific antibodies were equally
high before and after introduction of MenCC vaccine. However,
in the cohorts that received their MenCC immunization after the
tetanus booster at 9 years of age, a clear age-related increase and
persistence of tetanus-specific antibodies was observed, similar to
the MenC-specific antibody levels (Fig. 3).
Discussion
The immunization strategy in the Netherlands to prevent
meningococcal serogroup C disease with a single conjugate
MenC-Specific Seroprevalence
PLoS ONE | www.plosone.org 3 August 2010 | Volume 5 | Issue 8 | e12144Figure 1. MenC-specific IgG and serum bactericidal antibody levels. MenC PS-specific IgG (A) and seroprevalence of SBA titers $8 (B) within
each age-cohort, pre- and post-introduction of the MenC conjugate vaccine. Error bars indicate 95% confidence intervals. Between the vertical lines
cohorts are indicated that were all immunized in the catch-up campaign of 2002. Age at bloodsampling is indicated in years or as stated otherwise
(mo = age in months).
doi:10.1371/journal.pone.0012144.g001
MenC-Specific Seroprevalence
PLoS ONE | www.plosone.org 4 August 2010 | Volume 5 | Issue 8 | e12144vaccination at 14 months and a large catch-up campaign for all
children between 14 months and 18 years of age, has thus far been
highly successful in eliminating MenC disease in all age-categories
[1]. Data from the current study show that meningococcal
immunization leads to improved protection with age compared
to natural elicited immunity. However, serological protection
rapidly wanes within a few years after a single routine
immunization at 14 months of age. Immunization at an age
above 5 years of age seems to result in a prolonged persistence of
antibodies which gradually increases with age of immunization.
After a single vaccination at 14 months, a clear rise in IgG and
bactericidal antibodies is followed by a rapid decline in antibody
levels within a few years, which are comparable to levels before
introduction of the vaccine. In line with this, Snape et al showed
that after two years, residual bactericidal titers $8 remained
present in only 37% of children which were immunized around 2
years of age [8]. Nonetheless, we found a higher prevalence of
protective SBA titers, compared to the pre-MenC introduction
era, in these age-cohorts. This relatively high bactericidal activity
could furthermore almost completely be inhibited by pre-
absorbing the MenC PS-specific antibodies (data not shown).
This may be explained by the presence of antibodies with high
avidity or it points to a shift in the induction of highly functional
IgG1 antibodies compared to naturally elicited antibodies, that
persist after MenCC immunization despite low titers [20,21].
Thus, even without overall high serum IgG MenC levels,
conjugate vaccination may induce ongoing protection against
MenC disease.
Interestingly, we found a response that was related to the age of
MenCC immunization in children who were immunized between
5 and 18 years of age in the catch-up-campaign with a gradual
increase of antibody levels with age. This age-related persistence
was also found in the UK, in which Snape et al [9] and Trotter
and collegues [10] respectively, described a SBA prevalence of
84% and 67% in children vaccinated between 11–20 years, similar
to the 77% proportion of our study population. In Greece, Sakou
et al [22]. showed within the same age-group a slightly lower
prevalence of 62%. Differences in the seroprevalences between
studies are probably due to composition of the studies, percentage
of individuals immunized in each study and the use of different
meningococcal vaccines. The UK employed three different
MenCC vaccines, two of which are CRM197 (diphtheria toxin
mutant) conjugated vaccines, while only the tetanus conjugated
MenC vaccine is used in the Netherlands, which is more
immunogenic than the CRM197 conjugate vaccines [23–25].
The increase and persistence of circulating antibodies in the
age-cohort between 5 and 18 years might be explained by
nasopharyngeal carriage of, or exposure to, the meningococcal
Table 1. Number of samples within each age-cohort, GMCs and seroprevalence of MenC PS-specific IgG ($2 mg/ml) in the pre-
and post-MenC introduction eras.
Age Pre-introduction MenCC vaccine Post-introduction MenCC vaccine P-value*
No. samples GMC (95% CI) % samples $2 mg/ml No. samples GMC (95% CI) % samples $2 mg/ml Pre vs Post GMC
0–7 mo 35 0.17 (0.1220.24) 2.5 (0.0027.63) 202 0.04 (0.0320.05) 0.2 (0.0020.50) ,.0001
8–13 mo 98 0.16 (0.1320.20) 0.9 (0.0022.67) 163 0.03 (0.0220.04) 0 (NA) ,.0001
14–23 mo 77 0.18 (0.1520.20) 0.0 (NA) 88 1.87 (1.3922.51) 58.8 (48.13269.38) ,.0001
2 y 108 0.16 (0.1420.20) 0.9 (0.0022.63) 116 0.53 (0.3920.71) 12.5 (6.09218.93) ,.0001
3 y 123 0.16 (0.1420.19) 2.4 (0.0025.02) 142 0.43 (0.3320.57) 13.8 (8.39219.14) ,.0001
4 y 100 0.19 (0.1620.23) 1.1 (0.0023.29) 145 0.29 (0.2320.37) 5.5 (1.2329.73) ,.0001
5 y 80 0.20 (0.1520.26) 4.9 (0.0029.80) 95 0.31 (0.2520.38) 9.1 (4.71213.59 0.0106
6 y 84 0.27 (0.1920.38) 13.0 (4.39221.67) 107 0.25 (0.1920.31) 4.4 (0.0528.75) 0.2374
7–8 y 58 0.22 (0.1420.35) 6.9 (0.00216.15) 257 0.20 (0.1620.26) 5.4 (3.1327.67) 0.0527
9–10 y 49 0.28 (0.1820.44) 12.4 (2.18222.62) 244 0.36 (0.2620.51) 8.5 (4.73212.26) 0.0083
11–12 y 62 0.22 (0.1520.31) 9.6 (1.30217.85) 188 0.76 (0.6120.94) 27.0 (20.75233.36) ,.0001
13–14 y 73 0.28 (0.2120.36) 14.1 (6.33221.94) 159 0.80 (0.6121.06) 28.6 (20.83236.44) ,.0001
15–16 y 74 0.30 (0.1920.47) 18.7 (8.98228.44) 138 1.37 (1.0621.77) 39.0 (30.98246.99) ,.0001
17–18 y 61 0.40 (0.2320.67) 19.3 (7.26231.37) 113 2.14 (1.4923.07) 45.9 (36.50255.36) ,.0001
19–20 y 44 0.40 (0.2320.69) 18.7 (7.07230.31) 148 2.50(1.8623.35) 49.6 (41.98257.20) ,.0001
21–22 y 30 0.56 (0.3121.01) 31.2 (13.8248.53) 137 2.34 (1.7023.23) 50.5 (43.08257.82) 0.0003
23–25 y 70 0.64 (0.3921.06) 26.1 (15.5236.74) 185 0.16 (0.1120.23) 16.0 (9.78222.15) 0.0001
26–30 y 116 0.63 (0.4520.88) 29.1 (20.45237.70) 346 0.10 (0.0820.13) 9.7 (6.02213.34) ,.0001
31–39 y 205 0.38 (0.2820.52) 15.3 (9.64221.00) 658 0.11 (0.0920.13) 9.9 (7.29212.59) ,.0001
40–49 y 203 0.43 (0.3220.56) 20.9 (14.78227.05) 641 0.11 (0.0920.13) 8.3 (6.27210.41) ,.0001
50–59 y 202 0.40 (0.3220.50) 15.7 (9.84221.54) 714 0.10 (0.0920.11) 5.9 (3.92–7.96) ,.0001
60–69 y 182 0.37 (0.2520.55) 14.7(9.04220.39) 798 0.08 (0.0720.10) 4.2 (2.2626.16) ,.0001
70–79 y 171 0.38 (0.2920.49) 13.0 (7.44218.66) 592 0.10 (0.0920.11) 6.8 (4.8128.81) ,.0001
Total 2305 0.37 (0.3220.44) 16.8 (14.2219.4) 6376 0.17 (0.1620.18) 12.6 (11.7213.6) ,.0001
*P-values calculated for differences between IgG GMC pre- and post-introduction of the MenC vaccine with the Wilcoxon two-sided Z-test.
GMC, geometric mean concentration; NA, not applicable; mo, age in months; y, age in years.
doi:10.1371/journal.pone.0012144.t001
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natural priming of the maturing immune system [26]. Maturation
of the immune system throughout childhood has been extensively
described [27–29], and is suggested to be, together with ongoing
exposure of the immune-system, the most likely explanation of
enhanced antibody sustainment [9]. The small rise in MenC PS-
specific IgG from age 5 years onwards, as also observed in the pre-
MenC introduction era, underlines this maturation. However,
more than 4 years after MenCC immunization the levels of
circulating antibodies in this cohort are still remarkably high, while
for most other vaccines multiple dosages are required to reach
sustained protective levels for such a long period [30]. It may be
expected that antibody titers after infant immunization are not
sufficient enough to maintain seroprotection or herd-effects until
adolescence. Based on the results presented here, a booster
vaccination at an age just before adolescence - the age at which
carriage and disease incidence were historically highest -, may be
necessary to maintain protection on the long-term. Modelling
studies like that of Campbell et al [31]. are very useful for the
determination of the proper age at which a booster vaccination
can be administered. Although due to a single adolescent
immunization the transmission route for meningococci may
continue to be interrupted, it is probably not preferable to move
the immunization from the age of 14 months to an older age, or
completely remove this immunization from the NIP, since this
could potentially lead to an increase of meningococcal disease in
very young children.
We observed in cohorts immunized with the MenCC vaccine
between ages 10 to 18, who received a tetanus booster vaccination
at 9 years of age according to the Dutch NIP, also persistent high
levels of tetanus-specific antibodies compared to the levels
observed in the pre-MenC introduction era. Therefore, besides
the induction of immune memory by conjugate vaccination for the
polysaccharide antigen [32], conjugate vaccination at later ages
also induces long-lasting circulating antibodies towards the carrier
protein.
We observed a complete absence of MenC PS antibodies in the
first year of life before vaccination at 14 months of age, which was
even lower than the levels in the pre-MenC introduction era. This
is probably due to the decline in MenC PS-specific antibodies
observed in the population above 25 years of age, as a result of the
very low circulation of MenC after the mass immunization
campaign of 2002 among the Dutch population. The lack of
antibody levels in the first year of life may be compensated by
maternal antibodies, but women of childbearing age also currently
have low levels of MenC-specific IgG and SBA, leaving the
newborns vulnerable until the first vaccination at 14 months. In
the near future, when the MenCC immunized women are in the
childbearing age, the protection by maternal antibodies may
improve as high levels of maternal antibodies are observed in the
Table 2. Number of samples within each age-cohort, GMTs and seroprevalence of SBA (titers $8) in the pre- and post-MenC
introduction eras.
Age Pre-introduction MenCC vaccine Post-introduction MenCC vaccine P-value*
No. samples
a GMT (95% CI) % samples $8 No. samples GMT (95% CI) % samples $8 Pre vs Post % $8
0–7 mo 3 2 (NA) 0 (NA) 59 2 (NA) 0 (NA) NP
8–13 mo 13 2.1 (1.922.4) 0 (NA) 60 2.1 (1.922.4) 1.7 (0.0024.90) 0.6814**
14–23 mo 18 2.0 (NA) 0 (NA) 29 122.0 (59.92248.6) 89.7 (79.042100.00) ,.0001
2 y 24 2.0 (NA) 0 (NA) 42 13.1 (8.3220.8) 61.9 (49.24274.57) ,.0001
3–4 y 42 2.1 (1.922.4) 2.6 (0.0028.78) 106 5.4 (3.827.7) 30.2 (19.76240.62) ,.0001
5–6 y 34 2.8 (1.624.7) 6 (0.00216.38) 49 5.2 (3.427.8) 28.6 (14.44242.70) 0.0061
7–8 y 43 3.4 (2.225.2) 11.2 (2.73219.58) 56 5.1 (3.727.1) 33.9(23.18244.68) 0.0081
9–10 y 27 (30)
a 3.0 (1.326.9) 11.3 (0.00228.38) 73 9.4 (5.8215.2) 45.2 (31.66258.75) 0.0135
11–12 y 31 (32)
a 2.5 (1.424.5) 8.4 (0.00229.35) 72 20.0 (12.4232.2) 61.1 (51.19271.03) ,.0001
13–14 y 34 (35)
a 5.6 (2.1214.8) 23.5 (3.23243.83) 65 23.5 (15.9234.6) 69.2 (59.20279.26) ,.0001
15–16 y 38 (42)
a 3.3 (2.125.1) 16.3 (0.00235.54) 55 57.9 (36.7291.1) 81.8 (72.92290.71) ,.0001
17–18 y 25 3.6 (1.827.1) 11.7 (0.00226.93) 43 89.8 (58.42138.0) 86 (78.87293.22) ,.0002
19–21 y 21 (23)
a 2.6 (1.923.5) 5.9 (0.00214.56) 88 159.6 (109.12233.4) 95.5 (90.862100.00) ,.0001**
22–25 y 38 (44)
a 6.2 (3.1212.4) 26.1 (10.90241.30) 104 14.4 (9.1222.6) 49.0 (38.70259.38) 0.092
26–30 y 56 (62)
a 4.6 (2.1210.0) 24.5(8.76240.30) 69 4.2 (3.125.9) 26.1 (13.14239.03) 0.563
31–39 y 66 (67)
a 4.7 (3.825.8) 22.5 (17.98227.05) 58 3.6 (2.126.0) 19.0 (1.32236.61) 0.6376
40–49 y 65 (69)
a 5.3 (4.026.9) 26 (20.78231.30) 49 4.1 (2.526.7) 20.4 (8.28232.54) 0.2877
50–59 y 59 4.5 (3.925.2) 19.2 (13.64224.75) 52 4.1 (2.526.6) 21.2 (6.14236.17) 0.9105
60–69 y 51 5.9 (3.0211.5) 29.5 (11.85247.24) 54 3.2 (2.723.7) 18.5 (12.33224.71) 0.1894
70–79 y 48 3.6 (2.126.1) 17.1 (0.00237.18) 37 3.6 (2.525.4) 21.6 (6.11237.14) 0.7433
Total 736 (764)
a 4.3 (3.325.5) 19.8 (13.7226.0) 1220 10.2 (8.9211.7) 43.0 (39.5246.5) ,.0001
aNumber between brackets is the number of samples included in the seroprevalence calculation (% samples$8) and in not the GMT calculation, because only a SBA
titer $16 could be given for these samples.
*P-values calculated for differences between prevalence of SBA titers $8 pre- and post-MenC immunization with chi-square distribution, LR chi-square probability.
**Calculated with Fishers exact t-test.
GMT, geometric mean titer; NP, not possible; NA, not applicable; mo, age in months; y, age in years.
doi:10.1371/journal.pone.0012144.t002
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Age at bloodsampling is indicated in years or as stated otherwise (mo = age in months).
doi:10.1371/journal.pone.0012144.g002
Figure 3. Tetanus-specific IgG antibody levels. Tetanus-specific IgG levels in the pre- and post-MenC introduction eras and MenC PS-specific
IgG in the post-MenC introduction era within age-cohorts immunized during the catch-up campaign. All age cohorts were immunized in the catch-up
campaign of 2002.
doi:10.1371/journal.pone.0012144.g003
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with the estimated half-life of maternal IgG of 5 to 6 weeks,
antibody levels may still not be sufficient to provide protection
until the MenCC immunization at 14 months of age leaving
newborns at high risk for infection if the circulation of
meningococci of serogroup C increases again [34].
Non-immunized adult age-cohorts revealed distinctly lower
MenC-specific IgG than before introduction of MenC vaccination.
However, approximately 23% were still protected against disease
based on SBA prevalence. Inhibition of MenC PS-specific
antibodies revealed that this SBA result was not based on MenC
PS-specific antibodies alone as was seen in vaccinated infants (data
not shown). Therefore other naturally acquired antibodies are
assumed to play a prominent role in the immunity of adults [35].
Due to the current low circulation of MenC, specific antibody
levels may further decrease, putting these non-immunized adults at
increased risk in the (near) future if MenC returns in the
community.
Levels of MenY and Men W-135 PS-specific IgG were low
during life, which is expected based on the low carriage and
disease rates caused by these serogroups [36]. Still, with modern
travelling behaviour, a large migrant population and the rise of
serogroup Y in Northern America, awareness to the rise of other
serogroups should be maintained. As previously also observed by
Trotter et al [10], we saw increasing levels of MenA PS-specific
IgG during life, despite the fact that currently only a few cases of
MenA disease occur in the Netherlands. Several studies have
described that polysaccharides from other bacteria may elicit
cross-reactive antibodies towards the MenA PS [37–39], but to
what extend these antibodies are functional in preventing MenA
disease remains unclear.
The design of the studies ensured random selection of the
subjects. The MenCC vaccination coverage in the 40 municipal-
ities included in the serosurveillance study of 2006–2007
amounted up to 94% [3], which is similar for the overall coverage
achieved in 2002. Serum samples from those who participated in
the surveys are well characterized [15,16]. From all subjects (both
participants and non-participants) age and gender was known.
Although men in certain age groups participated less in both
surveys, we corrected for this by weighting the seroprevalence and
GMT estimates according to age and gender with data from
Statistics Netherlands. Furthermore persons who do not take part
in the NIP, participated somewhat less in both surveys (based on
the non-response questionnaire), thereby slightly overrepresenting
the subgroups who have a positive attitude towards vaccination.
Therefore, the seroprevalences may slightly be overestimated in
the cohorts that have been eligible for MenC vaccination.
However, as mentioned earlier 94% the general population was
immunized in 2002 against MenC and the current coverage in
the NIP is approximately 95% at 14 months, therefore little
differences may be expected. In addition, we found no significant
differences within the MenC eligible age-cohorts between the total
sampled population and the persons for whom a MenCC
immunization record was available (data not shown).
Conclusion
A single MenCC immunization leads to improved protection
compared to naturally elicited immunity. A single MenCC
immunization above 5 years of age seems to induce persistent
protective antibodies, whereas a single injection at 14 months leads
to a rapid waning within a few years of serological protective
levels. Since memory responses may not be fast enough to prevent
disease, antibody persistence by vaccination seems to be the major
way to prevent MenC disease [40–41]. If the incidence of MenC
disease increases due to renewed circulation, a MenCC booster
immunization just before entering adolescence may be appropri-
ate. A booster will most likely result in a high level of protective
bactericidal antibodies as previously shown in infants and
adolescents [40–42], and will probably preserve herd-effects,
which is requested for those who may be most susceptible to
disease, due to a lack of antibodies (cohorts under 14 months of
age). But most importantly, a second MenCC immunization will
also improve protection in the vaccinated cohorts, as in the years
to come a increasing part of children will be less well protected
since they received only a primary immunization at 14 months.
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